Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance.

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

Merck's Keytruda continued to pull its weight in the third quarter, helping deliver a beat and raise that could stoke Merck stock.

Here's How Merck's Heavyweight Cancer Drug Helped Deliver Another Beat-And-Raise Quarter

Merck (MRK) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $1.94 per share. This compares to earnings of $1.85 per share a year ago.

Merck (MRK) Q3 Earnings and Revenues Beat Estimates

Merck & Co Inc (NYSE:MRK)'s robust performance for the third quarter looks set to be greeted by Wall Street with a collective 'meh'. Premarket, the shares were down even though the drugmaker's numbers exceeded market expectations primarily due to strong demand for its COVID-19 antiviral pill, Lagevrio, in Japan.

Merck beats the Street; investor reaction is 'meh, whatever'

Merck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook.

Merck results beat expectations on strong Keytruda, Gardasil and Covid drug growth

Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on surprisingly strong demand for its COVID-19 treatment, primarily in Japan.

Merck 3rd-quarter profit tops expectations on COVID pill surprise

Merck & Co. on Thursday reported third-quarter results that topped analysts' expectations, powered by growth in oncology and vaccines.

Merck third-quarter results beat estimates, boosted by cancer drug and vaccine growth

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2023 Financial Results.

Merck Announces Third-Quarter 2023 Financial Results

Merck & Co. (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Merck & Co. (MRK) This Earnings Season?

Comcast

Valero Energy

Two of the seven stocks that have contributed 17% of the S&P 500's gains this year will report earnings after markets close on Tuesday.

Earnings Previews: Reports Coming Thursday Morning From Comcast, Merck, UPS, Valero Energy

Merck & Co. Inc. (NYSE:MRK ) October 22, 2023 1:00 PM ET Company Participants Peter Dannenbaum - VP, IR Dr. Dean Li - President, Merck Research Labs Eliav Barr - CMO & Head of Global Clinical Development, Merck Research Laboratories Marjorie Green - Senior VP & Head of Late-Stage Oncology, Global Clinical Development Jannie Oosthuizen - President, Human Health U.S. Conference Call Participants Umer Raffat - Evercore Luisa Hector - Berenberg Trung Huynh - UBS Conor MacKay - BMO Capital Markets Louise Chen - Cantor Chris Schott - J.P. Morgan Steve Scala - TD Cowen Chris Shibutani - Goldman Sachs Cerena Chen - Wells Fargo Operator Thank you for standing by.

Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript)

Almost 68% of patients responded to an experimental bladder cancer treatment from Merck and Seagen. Merck stock jumped Monday.

How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks

Daiichi Sankyo Co Ltd

Daiichi Sankyo has entered into a collaboration with Merck for three antibody-drug conjugates, bringing in a significant upfront payment and potential milestone payments. The three drugs in development, targeting HER3, B7-H3, and CDH6, have shown promising early-stage clinical data in various cancers. While there are risks associated with the efficacy and toxicity of these drugs, the collaboration with Merck provides financial security and further potential for success.

Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion

Chinese drugmaker Sichuan Kelun Pharmaceutical Co said on Monday that Merck & Co Inc was abandoning the joint development of two candidate cancer drugs which have yet to start clinical trials.

Merck discontinues some cancer drug development with China's Sichuan Kelun

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Vs. Chemotherapy in Patients With Previously Untreated la/mUC.

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's WELIREG® Significantly Improved PFS and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced RCC.

Merck's WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.

Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs

Drugmaker Merck (MRK) agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of the Japanese company's candidate cancer drugs.

Merck and Daiichi Sankyo Strike Cancer Drug Deal Worth Up to $22 Billion

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Plus Concurrent Chemoradiotherapy Significantly Improved PFS in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer.

Merck's KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

Gilead Sciences

Haleon PLC

Medtronic

Novartis

West Pharmaceutical Services

Zimmer Biomet Hlds

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

7 Healthcare Stocks to invest in for a Healthy Future

Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy achieved positive results as a treatment for patients with a rare form of esophageal cancer. The Phase 3 trial trial showed a statistically significant improvement in progression-free survival in the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, the company said, reducing the risk of death by 28% in a follow-up of 28.4 months.

Merck's Keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

RAHWAY, N.J.--(BUSINESS WIRE)--Neoadjuvant KEYTRUDA Plus Chemo Showed Statistically Significant Improvement in pCR Rate Vs Chemo in High-Risk, Early-Stage ER+/HER2- Breast Cancer.

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Trastuzumab and Chemo Significantly Improved PFS Versus Trastuzumab and Chemo in First-Line HER2+ Advanced Gastric or GEJ Cancer.

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemo Before Surgery & Continued as Single Agent After Surgery Reduced Risk of Death by 28% Vs Pre-Operative Chemo in Resectable NSCLC.

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)

Daiichi Sankyo shares 4568, +12.21% rose sharply after the Japanese drugmaker announced a multibillion dollar deal with Merck MRK, -1.53% to jointly develop and commercialize three cancer drug candidates.

News for Merck Stock (MRK)